14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BGLC vs CLBR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over CLBR (CLBR) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGLC carries a Unified Composite Score of 44.2/100 (HOLD) at $0.68 (N/M Forward P/E, -88.2% operating margin), whereas CLBR carries 47.5/100 (HOLD) at $10.02 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While CLBR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BGLC 44.2/100 HOLD), BGLC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-88.2% vs. N/A operating margin) and revenue trajectory (-96.6% vs. N/A YoY).
Technical & Structure Timing Caution: BGLC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.8); meanwhile CLBR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGLC vs CLBR. Trailing 12-month operating profitability (BGLC -88.2% vs CLBR N/A) and valuation multiples (BGLC N/M vs CLBR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BGLC vs CLBR Key Questions & Quantitative Answers
As of Nov 20, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over CLBR (CLBR) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGLC carries a Unified Composite Score of 44.2/100 (HOLD) at $0.68 (N/M Forward P/E, -88.2% operating margin), whereas CLBR carries 47.5/100 (HOLD) at $10.02 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CLBR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BGLC 44.2/100 HOLD), BGLC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-88.2% vs. N/A operating margin) and revenue trajectory (-96.6% vs. N/A YoY). Technical & Structure Timing Caution: BGLC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.8); meanwhile CLBR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BGLC leads the Growth & Scale pillar: BGLC posts -96.6% YoY revenue growth and -95.0% YoY earnings growth on $3.1M TTM revenue (12.3% gross margin, -88.2% operating margin), compared with CLBR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BGLC generates $3.1M in USD-normalized revenue versus N/A for CLBR. In operating R&D and SG&A reinvestment, BGLC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLBR.
BGLC and CLBR trade at balanced relative valuation multiples. BGLC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-38.1% FCF margin), whereas CLBR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGLC (-33.7% ROE) versus CLBR (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BGLC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 86% Vol realized risk). By comparison, CLBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 4% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.